Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Nat Clin Pract Endocrinol Metab. 2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities.

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

BRAF V600E mutations are common in different tumor ... including FISH- and real-time PCR-based methods. MAPK Pathway as Potential Therapeutic Target in Clinical Neuro-oncology Given the frequent ...

Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee recommended that the Company’s Phase 1 clinical trial of ...

In this review, after briefly summarizing the KRAS pathway and the mechanism of action ... leading to bypass of KRAS through gain-of-function mutations in other oncogenes such as NRAS, BRAF, and RET; ...

MIAMI - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a micro-cap biotech firm with a market capitalization of $2.63 million focusing on developing treatments for central nervous system disorders and ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen demonstrated a clinically meaningful and statistically significant improvement in confirmed NEW YORK ...